EVOLUTION

2021

  • Commenced operations at second API facility at Limbasi.
  • Third EU GMP inspection of our manufacturing facility located in Dholka.

2020

  • Board of the Company permitted the layout plan for the proposed injectable manufacturing unit at Valthera facility.
  • Received two ANDA approvals.
  • First shipment of Mycophenolate Sodium Tablets, in US market.

2019

  • Received two ANDA approvals.
  • Expansion of our company’s business in critical care segment in India.
  • Commencement of marketing of Mycophenolate Mofetil Capsules USP 250 mg.

2018

  • Fifth USFDA inspection and received ‘no action indicated’ classification for our facility located at Dholka.
  • Grant of GMP certification from Food and Drugs Control Administration for Valthera and Dholka units Second USFDA inspection at our facility located in Valthera facility and receipt of establishment inspection report.
  • Established Joint Venture in Japan pursuant to growing business opportunities in Japan.

2017

  • First USFDA inspection at our Valthera facility and receipt of establishment inspection report.

2016

  • Established a facility at Valthera, Gujarat.
  • Recognition of our in-house R&D facility located at Valthera by Ministry of Science and Technology, Government of India.
  • Investment from Helix

2015

  • Fourth USFDA inspection of our Dholka facility and conclusion of inspection as ‘closed’.
  • Second EU GMP inspection conducted in May 2014
  • Received accreditation certificate of foreign drug manufacturing for non-sterile drugs from Minister of Health, Labour and Welfare of Japan.

2014

  • Received certificate of drug substance registry for Ciclosporin JP from Pharmaceuticals and Medical Devices Agency, Japan.

2013

  • Third USFDA inspection and classification of our API facility as acceptable.

2012

  • Received original drug substance registration certificate for mycophenolate mofetil from Pharmaceuticals and Medical Devices Agency, Japan.

2011

  • First EU GMP inspection of our manufacturing facility by Government of Upper Bavaria- Central Medicines Control Bavaria (GMP/GCP).
  • Initiated CRAMs services in areas of new chemical entity (“NCE”) or Generic APIs.

2010

  • Received drug master file registration certificate for tacrolimus hydrate from Pharmaceuticals and Medical Devices Agency, Japan.

2008

  • Second USFDA inspection and classification of our API facility as acceptable.

2005

  • First USFDA inspection and classification of our API facility as acceptable.

2004

  • Investment by Rakesh Jhunjhunwala and Rekha Jhunjhunwala in our Company.

2003

  • Certification of our facility at Dholka for commissioning and commencement of production of various enzymes by technical consultants.

2002

  • Expansion of production capacity of enzymes

2001

  • Renaming of our Company to Concord Biotech Limited.

2000

  • Acquisition of our Company by Mr. Sudhir Vaid, one of our Promoters